https://orcid.org/0000-0002-5994-3957
Figures & data
Figure 1. Immunogenicity of three SARS-CoV-2 vaccinations in healthy individuals. (A) Plasma samples were tested for neutralizing capability against recombinant vesicular stomatitis virus (rVSV) pseudotyped with spike from non-variant SARS-CoV-2 with D614G mutation, SARS-CoV-2 variants, or SARS-CoV. (B) Plasma samples were tested for neutralizing capability against authentic non-variant SARS-CoV-2 (USA-WA1/2020) and SARS-CoV-2 variants in a cytopathic effect reduction assay. (C) Peripheral blood mononuclear cells (PBMC) were tested for SARS-CoV-2 spike protein-specific cellular immune responses by IFNγ ELISPOT. In all panels, average fold change in reciprocal plasma titre (ID50) or spot forming cells (SFC) between two timepoints are denoted. The limit of detection (LOD) in both neutralization assays is ID50 = 100 and in the ELISPOT is 55 SFC/106 PBMCs, and samples below the LOD are arbitrarily shown below the LOD to prevent overlapping datapoints. Colours denote individual vaccinees: blue = Vaccinee #1, red = Vaccinee #2, purple = Vaccinee #3, green = Vaccinee #4, orange = Vaccinee #5, brown = Vaccinee #6, grey = Vaccinee #7.
